This is an observational study of patients diagnosed with Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT) who are insufficiently responsive to monotherapy and who are prescribed GANfort® (fixed combination of 0.3 mg bimatoprost and 5 mg timolol) by their physician.
Study Type
OBSERVATIONAL
Enrollment
392
Patients with POAG or OHT prescribed GANfort® (fixed combination 0.3 mg bimatoprost and 5 mg timolol) treatment in a dose determined by the physician prior to study entry
Unnamed facility
Vienna, Austria
Change From Baseline in Intraocular Pressure (IOP)
IOP is a measurement of the fluid pressure inside the eye. A negative change from baseline indicates an improvement.
Time frame: Baseline, 18 Weeks
Physician Assessment of Tolerability Using a 4-Point Scale
Physician assessment of tolerability using a 4-point scale (very good, good, moderate, and poor). The number of patients assessed as good and very good combined are reported.
Time frame: 18 Weeks
Patient Assessment of Tolerability Using a 4-Point Scale
Patient assessment of tolerability using a 4-point scale (very good, good, moderate, and poor). The number of patients assessed as good and very good combined are reported.
Time frame: 18 Weeks
Physician Assessment of Adherence to GANfort®
Physician Assessment of Adherence to GANfort® was assessed on a 3-point scale (better, equal, and worse). The number of patients assessed as "better" compliance are reported.
Time frame: 18 Weeks
Patients Continuing With GANfort® After 18 Weeks
Patients continuing with GANfort® after 18 weeks was assessed as Yes or No.
Time frame: 18 Weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.